W
WAVEMAN · COMPANY
WVE · Wave Life Sciences, Inc.
> Ask across nine datasets ⌘K
LIVE
TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475
← ALL COMPANIES

WVE

Wave Life Sciences, Inc.
PHARMA & BIOTECH · PHARMACEUTICAL PREPARATIONS · CIK 0001631574
FORM 144 · 2☆ WATCH
INSIDER NET · 180D
$54.5M
open-market buys minus sells, Form 4 codes P and S
INSIDER BUYERS · 180D
1
CONGRESS BUYERS · 1Y
0
FUNDS ADDED · QTR
150
13F, latest reported quarter
REVENUE GROWTH
-60.5%
XBRL, annual
NET MARGIN
-478.3%
CONVERSIONS · 180D
2
codes C/M, not in net · $41.8K priced
SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST
INSIDERS
net +$54.5M over 180 days
-$135.1K over 90 days · +$54.6M of it by a 10%+ holder
more than 98% of Pharma & Biotech
CONGRESS
no member of Congress has reported trading it
FUNDS
150 funds added or opened last quarter
more than 78% of Pharma & Biotech
REVENUE
-60.5% year over year
below 86% of Pharma & Biotech
MARGIN
-478.3% net margin
below 82% of Pharma & Biotech
BUYBACKS
no share repurchases reported
SHORT
no short interest reported
THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET
150 funds added or opened positions in the latest 13F quarter, of 242 holders.
The year, with the filings on it
Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail
TOTAL 12M RETURN -49.5%
-49.5%12M
-51%+6%+64%+122%2025-092025-102025-122026-032026-052026-072026-09 2026-03-26 · RA CAPITAL MANAGEMENT, L.P. bought $30.0M2025-12-11 · GSK plc bought $27.9M2026-03-27 · RA CAPITAL MANAGEMENT, L.P. bought $16.0M2026-03-30 · RA CAPITAL MANAGEMENT, L.P. bought $6.3M2026-03-26 · RA CAPITAL MANAGEMENT, L.P. bought $2.2M2025-12-08 · Francis Chris sold $1.7M2025-12-08 · Francis Chris sold $1.6M2025-12-09 · Moran Kyle sold $1.0M2025-12-08 · Moran Kyle sold $900.0K2025-12-08 · Francis Chris sold $800.0K2025-12-08 · Moran Kyle sold $792.0K2025-12-08 · Moran Kyle sold $750.0K2025-12-08 · Francis Chris sold $665.3K2025-12-08 · Moran Kyle sold $660.0K2025-12-08 · Rawcliffe Adrian sold $630.0K2025-12-08 · HENRY CHRISTIAN O sold $540.6K2025-12-08 · HENRY CHRISTIAN O sold $535.5K2025-12-08 · Francis Chris sold $528.0K2025-12-08 · Francis Chris sold $407.8K2025-12-08 · Tan Aik Na sold $375.0K2025-12-08 · Francis Chris sold $316.8K2026-02-26 · Francis Chris sold $270.1K2025-12-08 · Francis Chris sold $268.5K2025-12-08 · Tan Aik Na sold $267.8K2025-12-08 · Tan Aik Na sold $258.4K2025-12-08 · Tan Aik Na sold $255.0K2026-02-26 · Francis Chris sold $229.4K2025-12-08 · HENRY CHRISTIAN O sold $211.1K2025-12-08 · Tan Aik Na sold $191.2K2025-12-08 · Verdine Gregory L. sold $157.3K2026-02-09 · BOLNO PAUL sold $141.0K2025-12-08 · Francis Chris sold $140.6K2026-01-02 · Francis Chris sold $128.6K2025-12-08 · CORRIGAN MARK sold $125.7K2025-12-08 · Tan Aik Na sold $112.4K2025-12-08 · Verdine Gregory L. sold $112.1K2025-11-13 · Rawcliffe Adrian sold $109.4K2025-12-08 · Wagner Heidi L sold $98.0K2025-12-08 · Tan Aik Na sold $95.5K2025-12-08 · CORRIGAN MARK sold $91.7K2025-12-08 · Wagner Heidi L sold $91.0K2025-12-08 · HENRY CHRISTIAN O sold $82.2K2026-08-12 · ADRIAN G RAWCLIFFE filed to sell $64.1K2026-08-11 · HEIDI L WAGNER filed to sell $42.5K
INSIDER BUYINSIDER SELLFORM 144
INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY
Live price
Daily candles from TradingView, on their licence — no filings are marked on this one
WHY THIS NAME IS ON THE DESK
Insiders are net buyers of their own stock.
The record shows a net $54.5M bought by insiders over 180 days, 150 funds added last quarter, $106.6K in planned Form 144 sales. Every figure is a federal filing, dated the day it became public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector from the SEC's own SIC classification
UTHRCPIXMRNAREGNLLYALNYELFCITRMDGLDNAVRTXNUVL
Insider transactions
Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

Over the last 180 days, Wave Life Sciences, Inc. insiders bought a net $54.5M of stock across 92 Form 4 purchases and sales, with 1 insider(s) buying. Source: SEC Form 4 filings, as of 2026-09-06.

INSIDER
FILED
SHARES
VALUE
Rawcliffe Adrian
Director
SELL
2026-08-12
12,700.0
$67.2K
Wagner Heidi L
Director
SELL
2026-08-11
7,000.0
$42.1K
TAKANASHI KEN
Director
SELL
2026-08-11
3,864.0
$23.2K
Tan Aik Na
Director
SELL
2026-08-11
432.0
$2.6K
RA CAPITAL MANAGEMENT, L.P.
Director
BUY
2026-03-30
971,091.0
$6.3M
92 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 87 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders
13F · holdings as of the latest quarter funds have reported
RA CAPITAL MANAGEMENT, L.P.
26,975,505.0 sh
$156.7M
BlackRock, Inc.
19,202,461.0 sh
$111.6M
GSK plc
18,245,691.0 sh
$106.0M
MAVERICK CAPITAL LTD
10,278,115.0 sh
$59.7M
Driehaus Capital Management LLC
5,443,143.0 sh
$31.6M
SCHEDULE 13D/G
No 5%+ ownership filings
Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.
Planned sales · Form 144
Filed before the sale — intent, not a trade
ADRIAN G RAWCLIFFE
FILED 2026-08-12
$64.1K
HEIDI L WAGNER
FILED 2026-08-11
$42.5K
Fund concentration
N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show
Global X Genomics & Biotechnology ETF
$786.3K POSITION · AS OF 2026-02-28
1.5%
PROFUND VP PHARMACEUTICALS
$96.4K POSITION · AS OF 2026-03-31
0.9%
Direxion Daily Pharmaceutical & Medical Bull 3X Shares
$86.5K POSITION · AS OF 2026-04-30
0.7%
AlphaCentric Life Sciences and Healthcare Fund
$211.5K POSITION · AS OF 2026-03-31
0.5%
NORTH SQUARE KENNEDY MICROCAP FUND
$130.6K POSITION · AS OF 2026-02-28
0.4%
Driehaus Small Cap Growth Fund
$5.0M POSITION · AS OF 2026-03-31
0.4%
SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK
Executive pay vs shareholder return · Paul Bolno
DEF 14A pay-versus-performance disclosure · both the headline pay and the SEC's mark-to-market figure, beside the return the company delivered and the return of the peer group it chose itself
FY
CEO TOTAL
ACTUALLY PAID
OTHER NEOs AVG
TSR
PEER TSR
2024
$4.3M
$17.4M
$1.8M
+57%
-65%
2023
$3.9M
$2.2M
$1.7M
-36%
-58%
2022
$2.7M
$6.1M
$1.2M
-11%
-54%
2021
$3.9M
$1.3M
$1.5M
-60%
-24%
TAGGED BY THE COMPANY UNDER SEC ITEM 402(v) · RETURN IS CUMULATIVE FROM THE START OF THE DISCLOSURE PERIOD · GREEN WHERE THE COMPANY BEAT ITS OWN PEER GROUP
Fundamentals
Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all
2025-122024-122023-122022-12
REVENUE$42.7M$108.3M$113.3M$3.6M
OPERATING INCOME$-215.4M$-110.4M$-68.0M$-162.7M
NET INCOME$-204.4M$-97.0M$-57.5M$-161.8M
EPS (DILUTED)-1.21-0.70-0.54-2.05
OPERATING CASH FLOW$-187.5M$-151.0M$-19.4M$-127.8M
CASH$602.1M$302.1M$200.4M$88.5M
SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-06 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE
W WAVEMAN

Public filings, honestly analyzed. Official US government sources in one desk — every figure carries the date it was filed, and the methodology is published, backtest included.

SEC FORM 4FORM 13F 13D/GFORM 144XBRL STOCK ACTCONTRACTSFEC CFPBNRC
PRODUCT
DeskBacktester CompaniesAccount
SUPPORT
FAQMethodology Contact
LEGAL
TermsPrivacy Accessibility
© 2026 WAVEMAN · SOURCE: SEC EDGAR & OFFICIAL GOVERNMENT DATA · NOT INVESTMENT ADVICE · CHART BY TRADINGVIEW · UPDATED 2026-09-06 ALL SYSTEMS LIVE FOR MACHINES →